Form 4: Innoviva Director Boosts Stake with RSU Grant

Innoviva Director Pavel Raifeld increased his beneficial ownership to 162,276 shares through an Employee Stock Purchase Plan acquisition and a significant restricted stock unit grant.

Summary

• Pavel Raifeld, a Director and 10% Owner of Innoviva, Inc. (INVA), reported changes in his beneficial ownership.
• On May 15, 2025, Raifeld acquired 1,860 shares of common stock under the Innoviva, Inc. Employee Stock Purchase Plan (ESPP) at a price of $0 per share.
• Following the ESPP acquisition, his beneficial ownership stood at 51,840 shares.
• On November 3, 2025, Raifeld was granted 110,436 shares of common stock as a time-vested restricted stock unit (RSU) at a price of $18.11 per share.
• After these transactions, Raifeld's total beneficial ownership increased to 162,276 shares.
• The RSU grant vests 25% on November 20, 2026, with the remaining balance vesting in twelve substantially equal installments every three months thereafter, contingent on continuous service.
• Accelerated vesting conditions apply in the event of a 'change in control' where the RSU is not assumed or replaced, or an 'involuntary termination' within 24 months following a 'change in control', subject to a release of claims.

Sentiment

Score: 7

Explanation: The filing reports an increase in beneficial ownership by a director through an RSU grant and ESPP, which generally signals positive insider confidence and alignment with shareholder interests. This is a routine compensation event rather than a direct market purchase, but still reflects a commitment to the company.

Positives

• A Director and 10% Owner increasing their stake through an RSU grant and ESPP acquisition demonstrates continued confidence in the company's future prospects.
• The RSU grant aligns management's interests with long-term shareholder value through its time-vested structure.

Risks

• The vesting of the restricted stock units is contingent upon the Reporting Person providing continuous service to Innoviva, Inc. through the applicable vesting dates.
• The value of the RSU grant is subject to the future market price of Innoviva's common stock.

Future Outlook

The RSU grant's vesting schedule, extending beyond November 2026, indicates a long-term commitment from the reporting person to the company's performance and continued service.

Management Comments

• The grant of the time-vested restricted stock unit was approved by the Compensation Committee of the Board of Directors of the Company.

Industry Context

Insider transactions, such as RSU grants and ESPP acquisitions, are common forms of executive compensation and employee benefits in the biotechnology and pharmaceutical industries. They are designed to align the interests of key personnel with those of shareholders by providing equity-based incentives tied to company performance and continued service.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased alignment of a key director's interests with long-term shareholder value through equity ownership.
• Employees: The ESPP acquisition highlights an employee benefit program, potentially encouraging broader employee participation in company ownership.

Next Steps

• The first tranche of the restricted stock units (25%) will vest on November 20, 2026.
• The remaining balance of the restricted stock units will vest in twelve substantially equal installments on each three-month anniversary of the initial vesting date.

Key Dates

Keywords

Innoviva, INVA, Form 4, Insider Transaction, Restricted Stock Unit, RSU, Employee Stock Purchase Plan, ESPP, Director, Beneficial Ownership